收缩
产品分类 PRODUCTS
产品展示PRODUCTS
您的当前位置:首页 > 产品展示 >> 骨代谢检测 >> 骨转换调节
生物活性骨硬化蛋白检测试剂盒(酶联免疫法)

人生物活性骨硬化蛋白检测试剂盒(酶联免疫法)

 

bioactive SCLEROSTIN ELISA

 

货号 BI-20472
方法学: Sandwich ELISA
样本类型: 血清,血浆(EDTA, citrate), 细胞培养上清液,尿液
标准品范围 0-320 pmol/l (7 serum based standards)
标准品: 0/10/20/40/80/160/320 pmol/l
质控品: 2个
样本量: 20 µl
孵育时间: 2 h / 1 h / 30 min
单位换算: 1 pg/ml = 0.044 pmol/l (MW: 22.5 kDa)

灵敏度:
LOD: 1.9 pmol/l (0 pmol/l + 3 SD); LLOQ: 1.3 pmol/l

精密度:
Intra-assay (n=3) ≤ 1%, Inter-assay (n=7) ≤ 5%

回收率:

The mean recovery of recombinant Sclerostin (spike: 26 pmol/l and 110 pmol/l) in human samples is:
serum (n=5): 93% / 86% 
EDTA plasma (n=5): 94% / 93% 
citrate plasma (n=1): 104% / 99% 

稀释线性:

Expected average dilution of recombinant Sclerostin in human samples for 1+1, 1+3 and 1+7 dilution is: 

serum (n=6): 98% / 86% / 89%
EDTA plasma (n=6): 102% / 99% / 91% 
citrate plasma (n=1): 119% / 132% / 103%

Expected average dilution of endogenous Sclerostin in human samples for 1+1, 1+3 and 1+7 dilution is: 
serum (n=7): 100% / 103% / 106%
EDTA plasma (n=6): 105% / 108% / 123% 
citrate plasma (n=2): 91% / 91% / 103%

交叉反应性: 
The assay does not detect Noggin.
The assay does not detect Wise (SOSTDC1).

健康人群血清样本参考值:
Median (serum, n=32): 61.5. pmol/l 
Median (EDTA plasma, n=24): 87 pmol/l
Median (citrate plasma, n=24): 61.5. pmol/l
推荐实验室建立自己的参考值。

Literature: 

1. Sclerostin and Wnt signaling-the pathway to bone strength.
Ott SM, et al.
J Clin Endocrinol Metab, 2005; 90(12):6392-6395
PMID: 16330810

2. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
Semenov M et al.,
J Biol Chem, 2005; 280(29):26770-26775.
PMID: 15908424

3. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation.
Veverka V et al.,
J Biol Chem, 2009; 284:10890-10900.
PMID: 19208630

4. Characterization of the Interaction of Sclerostin with the Low Density Lipoprotein Receptor-related Protein (LRP) Family of Wnt Co-receptors. Holdsworth G et al.,
J Biol Chem, 2012; 284(16), 287(32): 26464-26477.

5. New insights into the location and form of sclerostin.
Hernandez P et al.,
Biochem Biophys Res Commun, 2014; 446 (4):1108-1113.
PMID: 24667598

6. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women.
Durosier C et al.,
J Clin Endocrinol Metab, 2013; 98 (9):3873-3883.
PMID: 23864703

7. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.
van Lierop AH et al.,
J Clin Endocrinol Metab, 2012; 97:E1953-E1957.
PMID: 22844062

8. The Osteocyte: An Endocrine Cell … and More.
Dallas SL et al.,
Endocrine Rev, 2013; 34:658-690.
PMID: 23612223

9. Sclerostin in mineralized matrices and van Buchem disease.
van Bezooijen RL et al.,
J Dent Res, 2009; 88(6):569-574.
PMID: 19587164

10. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal.
Wergedal, JE et al.,
J Clin Endocrinol Metab, 2003; 88:5778.
PMID: 14671168

11. Circulating sclerostin in disorders of parathyroid gland function.
Costa AG et al.,
J Clin Endocrinol Metab, 2011; 96: 3804-3810.
PMID: 21937621

12. Serum sclerostin levels in Paget’s disease and prostate cancer with bone metastases with a wide range of bone turnover.
Yavropoulou MP et al.,
Bone, 2012; 51:153-157.
PMID: 22579776

13. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib. Monotherapy.
Terpos E et al.,
Int J Cancer, 2012; 131:1466-1471.
PMID: 22052418

14. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.
Van Lierop AH et al.,
Eur J Endocrinol, 2010; 163:833-837.
PMID: 20817762

15. Mechanical stimulation in vivo reduces osteocyte expression of Sost/sclerostin.
Robling AG et al.,
J Musculoskelet Neuronal Interact, 2006; 6(4):354.
PMID: 18089564

16. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.
Garnero P et al.,
Osteoporos Int, 2013; 13; 24(2):489-494.
PMID: 22525978

17. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults.
Amrein K et al.,
J Clin Endocrinol Metab, 2012; 97:148-154.
PMID: 21994959

18. Sclerostin and Dickkopf-1 in renal osteodystrophy.
Cejka D et al.,
Clin J am Soc Nephrol, 2012; 6: 877-882.
PMID: 21164019

19. The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD.
Pelletier S et al.,
Clin J am Soc Nephrol, 2013; 8 (5): 819-823.
PMID: 23430206

20. Renal elimination of Sclerostin increases with declining kidney function. Cejka D et al.,
J Clin Endocrinol Metab, 2014; 99(1):248-255.
PMID: 24187403

21. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.
Malluche HH et al.,
Clin J Am Soc Nephrol, 2014; 9:1254-1262.
PMID: 24948144

22. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
Kanbay M et al.,
J. Clin. Endocrinol Metab, 2014; 99:E1854-E1861.
PMID: 25057883

23. Sclerostin: Another bone-related protein related to all-cause mortality in haemodialysis?
Viaene L et al.,
Nephrol Dial Transplant, 2013; 28:3024-3030.
PMID: 23605174

24. Clinical utility of anti-sclerostin antobodies.
McClung MR, et al.
Bone, 2017; 96:3-7.
PMID: 28115281

25. Sclerostin measurement in human disease: Validity and current limitations. Costa AG et al.,
Bone, 2017; 96:24-28.
PMID: 27742501

26. Hormonal and systemic regulation of sclerostin.
MT Drake and S Khosla
Bone, 2017; 96:8-17.
PMID: 27965160

Back to top

REFERENCES, APPLICATIONS

Increased bioactive sclerostin levels in kidney transplant recipients detected with a new and well-characterized ELISA
ISN Frontiers Tokyo Feb 2018 - #P-300

首页公司简介新闻中心产品展示诚聘英才联系我们
© 版权所有 北京荣志海达生物科技有限公司
北京总部 电话:010-58895646 58895809 传真:010-58895611 电子邮箱:market@rz-biotech.com
广州营销中心 电话:020-32293176 32293178 传真:020-32293177 电子邮箱:sales@rz-biotech.com
京ICP备12047214 技术支持:完美网络